학술논문
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
Document Type
Artikel
Author
Source
British journal of haematology. 150(5):565-573
Subject
Language
English
English
English
ISSN
1365-2141